Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 17/20 | 0.87 |
| ▸ | MET | P08581 | 12/20 | 0.87 |
| ▸ | MERTK | Q12866 | 2/20 | 0.87 |
| ▸ | PLK4 | O00444 | 1/20 | 0.87 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.87 |
| ▸ | RET | P07949 | 1/20 | 0.87 |
| ▸ | KDR | P35968 | 1/20 | 0.87 |
| ▸ | FLT3 | P36888 | 1/20 | 0.87 |
| ▸ | MST1R | Q04912 | 1/20 | 0.87 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.87 |
| ▸ | CAMK4 | Q16566 | 1/20 | 0.87 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.87 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.87 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.87 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Merestinib SCHEMBL29493094 | 0.93 | AXL (1.00) | AXLMETMERTKPLK4NTRK1 | |
| Merestinib SCHEMBL679002 | 0.93 | AXL (1.00) | AXLMETMERTKPLK4NTRK1 | |
| SCHEMBL23629530 | 0.93 | AXL (0.75) | AXLMETMERTKPLK4NTRK1 | |
| SCHEMBL23629471 | 0.92 | AXL (0.88) | AXLMETMERTKPLK4NTRK1 | |
| Merestinib SCHEMBL680728 | 0.92 | AXL (0.99) | AXLMETMERTKPLK4NTRK1 | |
| Merestinib SCHEMBL29726013 | 0.92 | AXL (0.99) | AXLMETMERTKPLK4NTRK1 | |
| SCHEMBL23629478 | 0.92 | AXL (0.87) | AXLMETMERTKPLK4NTRK1 | |
| SCHEMBL23629476 | 0.91 | AXL (0.86) | AXLMETMERTKPLK4NTRK1 | |
| SCHEMBL23629546 | 0.91 | AXL (0.86) | AXLMETMERTKPLK4NTRK1 | |
| SCHEMBL23629405 | 0.91 | AXL (0.86) | AXLMETMERTKPLK4NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11952364-B2 | TRK inhibitors useful as anticancer drugs | TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED (CN) | 2024-04-09 | — | — | US | disclosed |
| CN-112739691-B | TRK inhibitors as anticancer agents | 泰励生物科技（上海）有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20220388983-A1 | TRK INHIBITORS USEFUL AS ANTICANCER DRUGS | TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED (CN) | 2022-12-08 | — | — | US | disclosed |
| US-20220388983-A1 | TRK INHIBITORS USEFUL AS ANTICANCER DRUGS | TYLIGAND BIOSCIENCE (SHANGHAI) LIMITED (CN) | 2022-12-08 | — | — | US | disclosed |
| EP-3848365-A1 | TRK INHIBITOR AS ANTI-CANCER DRUG | Tyligand Bioscience (Shanghai) Limited (CN) | 2021-07-14 | — | — | EP | disclosed |
| EP-3848365-A1 | TRK INHIBITOR AS ANTI-CANCER DRUG | Tyligand Bioscience (Shanghai) Limited (CN) | 2021-07-14 | — | — | EP | disclosed |
| CN-112739691-A | TRK inhibitors as anticancer agents | 泰励生物科技（上海）有限公司 | 2021-04-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11952364-B2 | TRK inhibitors useful as anticancer drugs | NTRK1, NTRK3, MUSK | AXL 187/4885MET 359/4885MERTK 111/4885 |
| US-20220388983-A1 | TRK INHIBITORS USEFUL AS ANTICANCER DRUGS | NTRK1, NTRK3, MUSK | AXL 187/4885MET 359/4885MERTK 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.